Mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) characterize the majority of LGGs and a small percentage of GBMs, and define subtypes that associate with better responses to radiation treatment and an improved prognosis compared with gliomas with wild-type (WT) IDH1–4. This evidence concerns the gene IDH1 and glioma.